{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Thrombotic+Thrombocytopenia&page=2",
    "query": {
      "condition": "Immune Thrombotic Thrombocytopenia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Thrombotic+Thrombocytopenia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:18:40.189Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00244257",
      "title": "Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "GMA161",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2005-08",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2015-04-09",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Diego, California • Bethesda, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244257"
    },
    {
      "nct_id": "NCT02281370",
      "title": "Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Purpura, Thrombocytopenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 39,
      "start_date": "2014-11-05",
      "completion_date": "2014-12-24",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281370"
    },
    {
      "nct_id": "NCT00774202",
      "title": "Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Rituxan, Cyclophosphamide, Vincristine, Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Higher Dose of Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 17,
      "start_date": "2003-11",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774202"
    },
    {
      "nct_id": "NCT06544499",
      "title": "A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo IV",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2024-10-18",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544499"
    },
    {
      "nct_id": "NCT01437384",
      "title": "Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura (ITP)"
      ],
      "interventions": [
        {
          "name": "E5501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01437384"
    },
    {
      "nct_id": "NCT00511147",
      "title": "IGIV Study for Chronic ITP Patients Ages 3-70",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "IGIV3I Grifols 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Biologicals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2008-05",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511147"
    },
    {
      "nct_id": "NCT00005652",
      "title": "Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Purpura, Thrombocytopenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2000-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-09-09",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005652"
    },
    {
      "nct_id": "NCT00621894",
      "title": "Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "LGD-4665",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2008-03-15",
      "completion_date": "2009-05-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-16",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 15,
      "location_summary": "San Diego, California • San Francisco, California • Manchester, Connecticut + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00621894"
    },
    {
      "nct_id": "NCT05086744",
      "title": "Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia (ITP)",
        "Cold Agglutinin Disease (CAD)"
      ],
      "interventions": [
        {
          "name": "Iptacopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 19,
      "start_date": "2021-12-21",
      "completion_date": "2024-05-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05086744"
    },
    {
      "nct_id": "NCT00002250",
      "title": "A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune Thrombocytopenic Purpura ( ITP )",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CD4-IgG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-23T18:18:40.189Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002250"
    }
  ]
}